Needham analyst Ami Fadia raised the firm’s price target on Intra-Cellular to $82 from $72 and keeps a Buy rating on the shares. The company announced a slight delay in the readout of the first of three major depressive disorder, MDD, studies from Q1 to April, though the firm retains its expectations for continued growth of Caplyta, upcoming data readouts in MDD, and progress of its pipeline in the medium/long term, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
- Intra-Cellular Therapies Business and Clinical Progress Update
- Intra-Cellular reports Q4 EPS (30c), consensus (44c)
- Notable companies reporting before tomorrow’s open
- Intra-Cellular price target raised to $82 from $76 at Mizuho